Parschauer Karah Herdman, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc. ($RARE), sold shares on the open market four times in the last year for a total of about $470 thousand. Her most recent $RARE insider sale occurred on March 10, 2026. Among nearly 12,000 insiders tracking open market stock sales, she ranks 6,599th with volume well below the average of $8.6 million across 6.4 transactions. No open market purchases in the past year.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 6, 2026 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 6018 | $21.40 | 70,328.0000 | 98,600,000 | 7.88% | 0.01% |
| March 10, 2026 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 3508 | $22.67 | 66,820.0000 | 98,600,000 | 4.99% | 0.00% |
| March 2, 2026 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 8135 | $22.80 | 76,346.0000 | 98,600,000 | 9.63% | 0.01% |
| March 1, 2026 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Common Stock | 11137 | $0.00 | 84,408.0000 | 98,600,000 | 15.20% | 0.01% |
| Feb. 17, 2026 | Evolus, Inc. | $EOLS | Parschauer Karah Herdman | Director | A | Common Stock | 45559 | $0.00 | 77,742.0000 | 64,819,784 | 141.56% | 0.07% |
| Sept. 12, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 2450 | $31.17 | 73,271.0000 | 90,538,118 | 3.24% | 0.00% |
| May 29, 2025 | Tenaya Therapeutics, Inc. | $TNYA | Parschauer Karah Herdman | Not found | A | Stock Option (Right to buy) | 107400 | $0.00 | 107,400.0000 | 87,582,646 | 9999.99% | 0.12% |
| March 12, 2025 | Evolus, Inc. | $EOLS | Parschauer Karah Herdman | Director | S | Common Stock | 12888 | $12.99 | 32,183.0000 | 63,586,753 | 28.59% | 0.02% |
| March 7, 2025 | Evolus, Inc. | $EOLS | Parschauer Karah Herdman | Director | A | Stock Option (Right to Buy) | 11146 | $0.00 | 11,146.0000 | 63,586,753 | 9999.99% | 0.02% |
| March 7, 2025 | Evolus, Inc. | $EOLS | Parschauer Karah Herdman | Director | A | Common Stock | 7364 | $0.00 | 45,071.0000 | 63,586,753 | 19.53% | 0.01% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Common Stock | 18443 | $0.00 | 88,133.0000 | 90,538,118 | 26.46% | 0.02% |
| March 3, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 12846 | $42.10 | 75,287.0000 | 90,538,118 | 14.58% | 0.01% |
| Feb. 27, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 760 | $42.75 | 54,991.0000 | 90,538,118 | 1.36% | 0.00% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Stock Option (Right to Buy) | 26074 | $0.00 | 26,074.0000 | 90,538,118 | 9999.99% | 0.03% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Common Stock | 14494 | $0.00 | 69,690.0000 | 90,538,118 | 26.26% | 0.02% |
| Feb. 27, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 2230 | $42.93 | 55,751.0000 | 90,538,118 | 3.85% | 0.00% |
| Oct. 18, 2024 | Tenaya Therapeutics, Inc. | $TNYA | Parschauer Karah Herdman | Not found | A | Stock Option (Right to buy) | 34000 | $0.00 | 34,000.0000 | 0 | 9999.99% | 0.00% |
| June 12, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 9806 | $45.00 | 57,981.0000 | 73,543,862 | 14.47% | 0.01% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Stock Option (Right to Buy) | 31400 | $0.00 | 31,400.0000 | 73,543,862 | 9999.99% | 0.04% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 3756 | $53.76 | 67,340.0000 | 73,543,862 | 5.28% | 0.01% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Common Stock | 957 | $0.00 | 70,739.0000 | 73,543,862 | 1.37% | 0.00% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Common Stock | 17800 | $0.00 | 69,782.0000 | 73,543,862 | 34.24% | 0.02% |
| Feb. 7, 2024 | Evolus, Inc. | $EOLS | Parschauer Karah Herdman | Director | A | Stock Option (Right to Buy) | 9377 | $0.00 | 9,377.0000 | 0 | 9999.99% | 0.00% |
| Feb. 7, 2024 | Evolus, Inc. | $EOLS | Parschauer Karah Herdman | Director | A | Common Stock | 6464 | $0.00 | 37,707.0000 | 0 | 20.69% | 0.00% |
| Jan. 30, 2024 | Evolus, Inc. | $EOLS | Parschauer Karah Herdman | Director | S | Common Stock | 11931 | $13.14 | 31,243.0000 | 0 | 27.63% | 0.00% |
| May 4, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 4378 | $45.00 | 51,982.0000 | 69,914,225 | 7.77% | 0.01% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Common Stock | 2663 | $0.00 | 37,101.0000 | 69,914,225 | 7.73% | 0.00% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | S | Common Stock | 3161 | $45.25 | 56,139.0000 | 69,914,225 | 5.33% | 0.00% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Stock Option (Right to Buy) | 39400 | $0.00 | 39,400.0000 | 69,914,225 | 9999.99% | 0.06% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | Common Stock | 22000 | $0.00 | 59,101.0000 | 69,914,225 | 59.30% | 0.03% |